Guangdong Tapai Group: 2024 Interim Performance Forecast

Sensex a shareJul 8 12:00 ET · Announcements

Express News | Guangdong Tapai Group Says H1 Net Profit Down 50-55% Y/Y

ReutersJul 8 05:32 ET

Guangdong Tapai Group (002233.SZ): Net income in the first half of the year is expected to decrease by 55%-50%.

Guangdong Tapai Group (002233.SZ) announced its performance forecast for the first half of 2024, with an estimated net income attributable to the company's shareholders of 0.219 to 0.243 billion yuan, a decrease of 55% to 50% from the same period last year; net income after deducting non-recurring gains and losses is 0.175 to 0.195 billion yuan, a decrease of 55% to 50% from the same period last year; basic earnings per share are 0.19 yuan/share to 0.21 yuan/share. The reason for the performance change is explained as follows: 1. The impact of the decline in profitability of the cement main business compared to the same period last year. In the first half of this year, affected by the continuous decline in real estate investment and the implementation of infrastructure projects.

Gelonghui FinanceJul 8 05:29 ET

CICC: The price increase in the two Guangdong provinces is expected to lead to further success. The profit expectation of the building materials sector is trending positively.

According to Zhuochuang, local cement companies in Guangdong are still able to make shipments, and leading companies still intend to raise prices to reduce losses. They plan to push for the second round of price increases for cement in the Pearl River Delta on June 26th.

Zhitong FinanceJun 26 02:38 ET

Guangdong Tapai Group (002233.SZ): The main business of Tapai Biology is the research and development, production, sales, and other business of functional probiotic products.

Guangdong Tapai Group (002233.SZ) stated on the investor interaction platform on June 17 that the company's main business of Tower Biotech is the research and development, production, and sales of functional probiotic products. As a beneficial microbe to the human body, functional probiotics have received widespread attention in the health industry in recent years. The company is bullish about the market prospects in this field and plans to cooperate with competitive research institutions in the industry to provide high-quality functional probiotic products to consumers. Currently, the team is being assembled and preparing for trial sales before launching the product. Subsequently, the company will gradually expand the promotion and sales of product categories and strive to create the number one brand.

Gelonghui FinanceJun 17 05:22 ET

Investors Aren't Buying Guangdong Tapai Group Co., Ltd.'s (SZSE:002233) Earnings

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Guangdong Tapai Group Co., Ltd. (SZSE:002233) as a highly attractive investment with it

Simply Wall StMay 24 19:22 ET